Table 2. Study design and mortality of mice challenged via the IN route with 2x105 PFU of MPXV.
Group | Cage | No. of Mice | Vaccine (T = 0) a | Booster (T = 23) b | MPXV Challenge (T = 50) c | Day of Death (RTC) d | MTD±SEM d | Mortality (%) |
---|---|---|---|---|---|---|---|---|
1 | 1 | 5 | N/T | N/T | PBS | |||
2 | 2 | 5 | N/T | N/T | + | 7,8,8,9,9 | 8.2±0.4 | 100 |
3 | 3 | 5 | Veh | Veh | + | 7,9,9,9,17 | 10.2±1.7 | 100 |
4 | 4 | 5 | MVA | Veh | ||||
5 | 5 | MVA | MVA | + | ||||
5 | 6 | 5 | A29L | Veh | 8,9,9,9 | 8.8±0.3 | 80 | |
7 | 41 | A29L | A29L | + | 7,10,10, | 9.0±1.0 | 75 | |
6 | 8 | 5 | M1R | Veh | 7,8 | 7.5±0.5 | 40 | |
9 | 5 | M1R | M1R | + | ||||
7 | 10 | 5 | B6R | Veh | 6,8,9 | 7.7±0.9 | 60 | |
11 | 4 e | B6R | B6R | + | 7,8 | 7.5±0.5 | 50 | |
8 | 12 | 5 | Combo | Veh | 7,8 | 7.5±0.5 | 40 | |
13 | 5 | Combo | Combo | + | 9 | 9.0 | 20 |
aBoHV-4 vaccines were administered at T = 0 days via the IP route in a total volume of 0.3 ml at 1x107 PFU. MVA was administered at a dose of 2x107 PFU in a total volume of 0.1 ml injected IM. Veh indicates a DMEM vehicle.
bBooster vaccinations were administered as for a.
cMice were challenged via the IN route with 2x105 PFU of MPXV. Virus was introduced in a total volume of 25 #x03BC;l to one nare.
dRTC, relative to challenge; MTD, mean time to death; SEM, standard error of the mean.
eOne mouse was removed due to mortality during blood collection.